Loading...
01/10 15:46
Loading...
Protalix Biotherapeutics Inc (PLX) is set to release its earnings performance on 08/14 04:00:00 in Pre-Market trading. Consensus forecasts predict a revenue of 13.49M and an earnings per share (EPS) of 0.03 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
The earnings call reveals mixed signals: increased R&D expenses and net loss improvement are positive, but unclear responses on revenue guidance and cash burn are concerning. The positive outlook for PRX-115's market potential and Elfabrio's potential EMA approval are offset by limited visibility on financial metrics. The Q&A section highlights uncertainties, with management's evasive answers potentially dampening investor confidence. Overall, the stock is likely to remain stable, resulting in a neutral sentiment.
The earnings call presents a mixed picture: increased revenues and a return to profitability are positive, but higher R&D expenses and unclear management responses in the Q&A raise concerns. While strong sales to Chiesi and improved net income are encouraging, the lack of guidance on key strategic areas and potential financial strain from increased R&D costs suggest a cautious outlook. The absence of a new partnership announcement or significant guidance changes also tempers enthusiasm, leading to a neutral sentiment prediction.
The earnings call reveals several concerns: missed EPS expectations, increased R&D expenses, and significant supply chain costs. While revenue from selling goods increased, the cost of goods sold rose dramatically, indicating potential operational inefficiencies. The Q&A session highlighted uncertainties in regulatory outcomes and vague management responses, further undermining confidence. Despite some positive revenue growth, the lack of a share repurchase program and financial instability suggest a negative outlook for the stock price.
The earnings call summary presents a mixed picture: strong revenue growth and improved net loss are positive, but rising costs, regulatory uncertainties, and lack of shareholder return plan weigh negatively. The Q&A session reveals management's evasive responses on key issues, adding uncertainty. While revenue from key partnerships is promising, the absence of clear guidance and potential supply chain challenges temper optimism. The stock price is likely to remain stable, as positive and negative factors balance out, resulting in a neutral sentiment.
Protalix Biotherapeutics Inc (PLX) is scheduled to release its FY2025Q2 earnings report onAug 14, 2025, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
Analysts' consensus predicts 13.49M in revenue and an EPS of 0.03 for Protalix Biotherapeutics Inc's FY2025Q2.
Intellectia's exclusive AI algorithms forecast a forProtalix Biotherapeutics Inc's FY2025Q2 earnings, with a prediction date of Aug 14, 2025. Protalix Biotherapeutics Inc
Leverage Intellectia's AI forecast to position trades ahead of theAug 14, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
Each prediction includes a detailed rationale, key indicator forecasts, and scenario probabilities to guide your trades. For a *Beat*, consider buying call options or shares; for a *Miss*, explore puts or hedging strategies. The prediction card provides actionable suggestions, like specific option strikes or hedging tips, tailored to your risk tolerance. Trade smart and turn insights into profits!
